Saturday, June 19, 2021 : Issue #1142

TOP STORIES - Diabetes News & Research

Overlooked Risk Factors for Type 2 Diabetes

Fruit Consumption and Incidence of Type 2 Diabetes

The Risk Factor Responsible for Half of America's Diabetes Cases

Letter from the Editor

David Joffe, Editor

I was looking over some old CE programs I have done for nurses and pharmacists on diabetes. One of the programs I had presented was on the relationship of sleep apnea and diabetes. We discussed the increased incidence of diabetes in patients with sleep apnea, and how the research actually showed a causative effect.

This week, our intern Alexandria Bartley from FAMU College of Pharmacy looked at some newer information on what disease states cause an increase in the development of diabetes. One of those causes was insomnia and poor sleep quality. To learn what other diagnoses can lead to increased development of diabetes, click here for our Laterpay feature.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Did You Know: what happens when you de-intensify or stop statin therapy?

Practice guidelines recommend that most patients receive moderate- or high-potency statins after ischemic stroke or transient ischemic attack (TIA) of atherosclerotic origin. This study looked at the association of different patterns of potency for prescribed statin therapy--assessed before admission and at hospital discharge for ischemic stroke or TIA--on mortality in a large, nationwide sample of US Veterans.

The study population included patients with an ischemic stroke or TIA occurring during 2011 at any of 134 Veterans Health Administration facilities. The study categorized statin dosing as low, moderate, or high potency; moderate or high potency was considered a goal. Six mutually exclusive groups were created to reflect patterns of statin potency from hospital admission to discharge: goal to goal, low to goal, goal to low or goal to none (deintensification), none to none, none to low, and low to low. Logistic regression was used to compare 30-day and 1-year mortality across statin potency groups.

The population included 9380 predominately White (71.1%) male (96.3%) patients hospitalized for stroke or TIA. In this sample, 34.1% of patients (n=3194) were discharged off a statin medication. Deintensification occurred in 14.0% of patients (n=1312) and none to none in 20.5% (n=1924). Deintensification and none to none were associated with a higher odds of mortality as compared with goal to goal (adjusted odds ratio 1-year mortality: deintensification versus goal to goal, 1.26 [95% CI, 1.02-1.57]; none to none versus goal to goal, 1.59 [95% CI, 1.30-1.93]). Adjustments for differences in baseline characteristics using weighted propensity scores demonstrated similar results.

Underutilization of statins, including no treatment or underdosing after stroke (deintensification), was observed in approximately one-third of veterans with ischemic stroke or TIA and was associated with higher mortality when compared with patients who were at goal for statin prescription dosing. Stroke May 2021

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Damisha Henderson, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Fourth Year PharmD Candidate

Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy

Laura Martínez López, PharmD. Candidate 2021, Lake Erie College of Osteopathic Medicine, College of Pharmacy

George McConnell, PharmD. Candidate, LECOM School of Pharmacy

Brenda Oppong, PharmD Candidate, LECOM School of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com

Diabetes In Control
2093 Philadelphia Pike #8370
Claymont, DE, 19703, United States

DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

Saturday, June 19, 2021 : Issue #1142

TOP STORIES - Diabetes News & Research

TOP STORIES - Diabetes News and Research

Did You Know: what happens when you de-intensify or stop statin therapy?

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: